News

Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes in multiple

The primary endpoint of the Phase 2 study is overall survival. A preliminary analysis of data from the study showed a difference in survival favoring the placebo plus

Bosutinib is an oral, once-daily, investigational dual Src and Abl kinase inhibitor with minimal inhibitory activity against c-kit and PDGFR. By dual inhibition of the Src and Abl

Under the term sheet for the co-promotion and sale agreement, Apricus will receive rights to co-promote Granisol and AQUORAL in the US, with exclusive promotion rights in certain

As per the extension, Novartis will fund research at GenVec through January 2013 to support its hearing loss and balance disorders program. GenVec has entered into a worldwide

INLYTA is an oral therapy designed to selectively inhibit vascular endothelial growth factor receptors 1, 2 and 3, which can influence tumor growth, vascular angiogenesis and progression of

Xiaflex (collagenase clostridium histolyticum) is a biologic for the treatment of adult Dupuytren’s contracture patients with a palpable cord. Xiaflex treatment is intended to target and lyse, or

Tasimelteon is a circadian regulator in development for the treatment of Non-24-Hour Disorder in totally blind individuals with no light perception. This observation was made in four patients

CPX-351 is the Celator’s proprietary ‘liposomal combination of cytarabine and daunorubicin’ injection, indicated to treat acute myeloid leukemia (AML). The designation follows a positive opinion from the Committee